Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States.
High growth potential with adequate balance sheet.
Share Price & News
How has Incyte's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: INCY's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: INCY underperformed the Austrian Biotechs industry which returned 35.8% over the past year.
Return vs Market: INCY exceeded the Austrian Market which returned -18.2% over the past year.
Price Volatility Vs. Market
How volatile is Incyte's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Incyte undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: INCY (€87.53) is trading below our estimate of fair value (€115.36)
Significantly Below Fair Value: INCY is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: INCY is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: INCY is unprofitable, so we can't compare its PE Ratio to the Austrian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate INCY's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: INCY is overvalued based on its PB Ratio (11.1x) compared to the XE Biotechs industry average (4.4x).
How is Incyte forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: INCY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.5%).
Earnings vs Market: INCY is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: INCY's is expected to become profitable in the next 3 years.
Revenue vs Market: INCY's revenue (16.8% per year) is forecast to grow faster than the Austrian market (3.6% per year).
High Growth Revenue: INCY's revenue (16.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: INCY's Return on Equity is forecast to be high in 3 years time (25.6%)
How has Incyte performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: INCY is currently unprofitable.
Growing Profit Margin: INCY is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: INCY is unprofitable, but has reduced losses over the past 5 years at a rate of 18.4% per year.
Accelerating Growth: Unable to compare INCY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INCY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (17.1%).
Return on Equity
High ROE: INCY has a negative Return on Equity (-19.41%), as it is currently unprofitable.
How is Incyte's financial position?
Financial Position Analysis
Short Term Liabilities: INCY's short term assets ($1.7B) exceed its short term liabilities ($503.4M).
Long Term Liabilities: INCY's short term assets ($1.7B) exceed its long term liabilities ($311.3M).
Debt to Equity History and Analysis
Debt Level: INCY's debt to equity ratio (1%) is considered satisfactory.
Reducing Debt: INCY had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if INCY has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if INCY has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Incyte's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate INCY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate INCY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if INCY's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if INCY's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of INCY's dividend in 3 years as they are not forecast to pay a notable one for the Austrian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Hervé Hoppenot (59yo)
Mr. Hervé Hoppenot has been the Chairman of the Board at Incyte Corporation since May 2015 and as its Chief Executive Officer and President since January 13, 2014. Mr. Hoppenot served as the Chief Commerci ...
CEO Compensation Analysis
Compensation vs Market: Hervé's total compensation ($USD15.15M) is above average for companies of similar size in the Austrian market ($USD3.83M).
Compensation vs Earnings: Hervé's compensation has increased whilst the company is unprofitable.
|Executive VP & CFO||1.33yrs||US$4.50m||0.00097% $185.5k|
|Executive VP & Head of Discovery Chemistry||5.67yrs||US$6.95m||0.014% $2.8m|
|Executive VP & GM of North America||5yrs||US$5.44m||0.0014% $265.9k|
|Executive VP & Chief Medical Officer||5.25yrs||US$7.04m||0.0012% $221.9k|
|Executive VP & Head of Global Technical Operations||4.42yrs||no data||0.016% $3.0m|
|Executive VP & Chief Scientific Officer||1.5yrs||no data||0.00055% $105.2k|
|Divisional Vice President of Investor Relations & Corporate Social Responsibility||6.25yrs||no data||no data|
|Executive VP & General Counsel||2.17yrs||US$3.62m||0.0013% $254.4k|
|Vice President of Investor Relations & Corporate Communications||no data||no data||no data|
Experienced Management: INCY's management team is seasoned and experienced (5 years average tenure).
|Independent Director||5.42yrs||US$522.45k||0.0035% $677.1k|
|Lead Independent Director||no data||US$559.70k||0.26% $49.3m|
|Independent Director||3.42yrs||US$526.06k||0.0015% $292.7k|
|Independent Director||18.58yrs||US$518.28k||0.12% $23.8m|
|Independent Director||10.08yrs||US$526.30k||0.0059% $1.1m|
|Independent Director||0.50yr||US$171.31k||0.00031% $59.3k|
|Independent Director||0.25yr||no data||no data|
|Independent Director||5.42yrs||US$536.49k||0.0013% $241.0k|
Experienced Board: INCY's board of directors are considered experienced (5.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Incyte Corporation's company bio, employee growth, exchange listings and data sources
- Name: Incyte Corporation
- Ticker: INCY
- Exchange: WBAG
- Founded: 1991
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$21.483b
- Listing Market Cap: US$19.128b
- Shares outstanding: 217.37m
- Website: https://www.incyte.com
Number of Employees
- Incyte Corporation
- 1801 Augustine Cut-Off
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|INCY||NasdaqGS (Nasdaq Global Select)||Yes||Common Shares||US||USD||Nov 1993|
|ICY||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Nov 1993|
|INCY||WBAG (Wiener Boerse AG)||Yes||Common Shares||AT||EUR||Nov 1993|
|0J9P||LSE (London Stock Exchange)||Yes||Common Shares||GB||USD||Nov 1993|
|ICY||ETLX (Eurotlx)||Yes||Common Shares||IT||EUR||Nov 1993|
|INCY *||BMV (Bolsa Mexicana de Valores)||Yes||Common Shares||MX||MXN||Nov 1993|
|I1NC34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EACH 2 REPR 1 COM||BR||BRL||Jan 2020|
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. Further, it is involved in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; MorphoSys AG; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; and Zai Lab Limited. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/04 11:11|
|End of Day Share Price||2020/06/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.